A Randomized Controlled Trial of Bilateral Subthalamic Stimulation in Patients With Parkinson's Disease and Impulse Control Disorders

Status: Recruiting
Location: See all (12) locations...
Intervention Type: Procedure, Drug
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

The focus of the study is on patients Parkinson's disease showing as well behavioral disorders that can be described as pathological and are summarized under the term impulse control disorder (ICD). Changes in behavior and also pathological disorders are a common side effect of treatment for Parkinson's disease. The goal of this academic study is to compare the effect of surgical (deep brain stimulation, DBS) treatment combined with a coordinated and adapted best medical treatment (BMT) to be compared with the effect of optimized best medical treatment (BMT) alone. The stimulation arm (DBS+BMT) as well as the medication arm (BMT only) will be monitored according to clinical routine. Participants will have to agree to be randomly assigned to either deep brain stimulation in combination with the best medical treatment (DBS group) or the best medical treatment alone (BMT group). Participants will have to come regularly according to clinical routine to the clinic and complete various questionaires and scales for the study.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 70
Healthy Volunteers: f
View:

• Age at the time of enrollment: ≤ 70 years

• Duration of idiopathic Parkinson's disease ≥ 4 years diagnosis of PD acc. MDS clinical diagnostic criteria

• Moderate or severe impulse control disorder or related behavioral disorders according to Ardouin, with at least 1 score greater than or equal to 3 (or at least 2 scores greater than or equal to 2) on the Ardouin behaviour scale with the following items considered to reflect ICBDs or related behaviors: pathological gambling, hypersexuality, shopping, eating, hobbyism, punding and compulsive medication use

• MDS-UPDRS III improvement of ≥ 30% in the standardized levodopa test

• MoCA ≥ 24 in the meds on condition

• BDI-II score \< 20 in the meds on condition, or Patients with moderately severe depression with a BDI-II between 20 and 28 points, strict consideration must be made with the involvement of a psychiatrist. Patients must be willing and able to comply this.

• Patients able to understand the study requirements and the treatment procedures

• Written informed consent before any study-specific tests or procedures are performed

Locations
Other Locations
Germany
University Hospital Cologne
RECRUITING
Cologne
University Hospital Carl Gustav Carus
RECRUITING
Dresden
University Hospital Duesseldorf
RECRUITING
Düsseldorf
University Medical Center Hamburg-Eppendorf
RECRUITING
Hamburg
University Hospital Schleswig-Holstein (UKSH), Campus Kiel
RECRUITING
Kiel
University Hospital of Giessen and Marburg (UKGM), Campus Marburg
RECRUITING
Marburg
Charité Campus Mitte
RECRUITING
Mitte
University Hospital Tuebingen
NOT_YET_RECRUITING
Tübingen
University Hospital Wuerzburg
RECRUITING
Würzburg
Netherlands
Amsterdam University Medical Center
NOT_YET_RECRUITING
Amsterdam
Switzerland
University Hospital of Bern (Inselspital)
RECRUITING
Bern
University Hospital Zuerich (USZ)
RECRUITING
Zurich
Contact Information
Primary
Steffen Paschen, MD
steffen.paschen@uksh.de
+49 (0)431 500
Backup
Guenther Deuschl, Prof.
g.deuschl@neurologie.uni-kiel.de
Time Frame
Start Date: 2024-09-05
Estimated Completion Date: 2028-07-15
Participants
Target number of participants: 60
Treatments
Other: DBS-group
Within indication and clinical routine:~bilateral high frequency deep brain stimulation of the subthalamic nucleus combined with best medical treatment
Other: BMT-group
Within indication and clinical routine:~best medical treatment
Sponsors
Collaborators: Philipps University Marburg, University Hospital Schleswig-Holstein, Insel Gruppe AG, University Hospital Bern, Amsterdam University Medical Centers (UMC), Location Academic Medical Center (AMC), Czech Technical University in Prague, University of Pennsylvania
Leads: University of Kiel

This content was sourced from clinicaltrials.gov